中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (7): 522-523.doi: 10.12144/zgmfskin202507522

• 病例报告 • 上一篇    下一篇

单用托法替布成功治疗寻常型天疱疮一例

曹珊1,2,赵晴1,2,槐鹏程1,2,张福仁1,2   

  1. 1山东第一医科大学附属皮肤病医院，山东济南，250022；2山东省皮肤病性病防治研究所，山东济南，250022
  • 出版日期:2025-07-15 发布日期:2025-07-07

Tofacitinib monotherapy successfully treated pemphigus vulgaris: a case report

CAO Shan1,2, ZHAO Qing1,2, HUAI Pengcheng1,2, ZHANG Furen1,2   

  1. 1 Dermatology Hospital of Shandong First Medical University, Jinan 250022, China; 2 Shandong Provincial Institute of Dermatology and Venereology, Shandong Academy of Medical Sciences, Jinan 250022, China
  • Online:2025-07-15 Published:2025-07-07

PDF (PC)

39

摘要： JAK抑制剂是一种针对非受体型酪氨酸激酶家族的药物，因影响细胞增殖存活及免疫细胞分化而被尝试治疗多种疾病。本文报道一例单用JAK抑制剂托法替布成功治疗寻常型天疱疮患者，托法替布治疗2个月后黏膜损害完全好转。

关键词: JAK抑制剂, 托法替布, 寻常型天疱疮

Abstract: JAK inhibitors are medications targeting the Janus kinase family of non-receptor tyrosine kinases, which influences cell proliferation, and immune cell differentiation. We report a case of pemphigus vulgaris who was successfully treated with tofacitinib monotherapy. Complete resolution of mucosal lesions after two months of tofacitinib treatment.

Key words: JAK inhibitor, tofacitinib, pemphigus vulgaris